Plain-English translation of NCT06792643 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to prevent blood clots in patients who have had a severe heart attack and are receiving mechanical heart-lung support (called VA-ECMO). The medication works by blocking platelet activation, which is a key step in clot formation. Researchers are studying whether this treatment is safe and effective when added to standard blood-thinning therapy in this very sick patient population.
Patients on mechanical heart support face a dangerous balancing act: their blood is at high risk for forming clots (which can cause strokes or device failure), but they also bleed more easily. Current standard treatments may not be strong enough to prevent clots without causing too much bleeding. This trial is exploring whether this medication can better protect these patients without increasing life-threatening bleeding.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the new medication through an IV line while you are already receiving other standard blood-thinning treatments and mechanical heart support. The medication dose would be carefully adjusted based on blood tests that measure how well your platelets are functioning. Your medical team would closely monitor you for both blood clots and bleeding complications throughout your hospital stay.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
Italy